{
    "Trade/Device Name(s)": [
        "Automated Glycohemoglobin Analyzer HLC-723G8"
    ],
    "Submitter Information": "Tosoh Bioscience, Inc.",
    "510(k) Number": "K131580",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121291"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "January 23, 2014",
    "Summary Letter Received Date": "December 20, 2013",
    "Submission Date": "December 20, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Automated Glycohemoglobin Analyzer HLC-723G8"
    ],
    "Method(s)/Technology(ies)": [
        "High Performance Liquid Chromatography (HPLC)",
        "Non-porous ion-exchange HPLC",
        "Cation exchange chromatography"
    ],
    "Methodologies": [
        "Chromatographic separation"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Tosoh Bioscience Automated Glycohemoglobin Analyzer HLC-723G8 for quantitative measurement of Hemoglobin A1c in whole blood",
    "Indications for Use Summary": "Intended for in vitro quantitative measurement of hemoglobin A1c in whole blood specimens as an aid in diagnosis of diabetes and identifying patients at risk for developing diabetes",
    "fda_folder": "Clinical Chemistry"
}